NCT06188741 2026-03-12
NF114
University of Alabama at Birmingham
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
NCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01362803 2026-03-02
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT04924608 2026-01-12
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT06763315 2025-01-08
LS-NF1PNs
West China Hospital
Phase 2 Not yet recruiting
NCT05825365 2023-08-14
PROTECT
AstraZeneca
Phase 2 Withdrawn
NCT03109301 2019-04-05
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn